Amir Prushani
Gastroenterology · Philadelphia, PANPI 1275762858
Payments from drug & device makers
Across 80 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$686
- Johnson & Johnson$307
- Takeda Pharmaceuticals U.S.A., Inc.$241
- Gilead$136
- Phathom Pharmaceuticals, Inc.$118
- Ipsen Biopharmaceuticals, Inc$71
- plus $378 from 9 others
What the payments were for
- Food & beverage$1,937100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $686 |
| Johnson & Johnson | 12 | $307 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $241 |
| Gilead | 9 | $136 |
| Phathom Pharmaceuticals, Inc. | 5 | $118 |
| Ipsen Biopharmaceuticals, Inc | 3 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $69 |
| Novo Nordisk | 2 | $54 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
| Pfizer | 2 | $46 |
| Madrigal Pharmaceuticals | 1 | $46 |
| Regeneron Healthcare Solutions, Inc. | 1 | $40 |
| Lilly USA, LLC | 1 | $31 |
| QOL Medical, LLC | 1 | $24 |
| Organon | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$114
How this compares
$1,937 in reported general payments places this provider in the 45th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 41 | $7,041 |
| Mesalamine | 17 | $6,931 |
| Ursodiol | 19 | $5,561 |
| Sucralfate | 46 | $1,547 |
| Pantoprazole Sodium | 110 | $1,411 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 23 | $520 |
| Omeprazole | 32 | $388 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 18 | $296 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 11 | $150 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Philadelphia
- Kuchikala ReddyPhiladelphia$6.5M
- Dina Halegoua de MarzioPhiladelphia$1.5M
- Gary FalkPhiladelphia$1.4M
- Kristle LynchPhiladelphia$1.3M
- Gary WuPhiladelphia$931K
- Faten AberraPhiladelphia$909K
- Ben StangerPhiladelphia$815K
- David KaplanPhiladelphia$737K
- Stacey PrennerPhiladelphia$577K
- Mark OstermanPhiladelphia$410K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.